ACTRIMS 2021 | What’s to come in the MS field?
Carlos Pérez
• 25 Feb 2021
Carlos Pérez, MD, The University of Texas Health Science Center at Houston, Houston, TX, shares his thoughts on what is to come in the multiple sclerosis (MS) field in the next few years. He highlights BTK inhibitors as promising agents that could address unmet needs in MS. Dr Pérez also says we are likely to see data on how novel agents effect different racial and ethnic groups, an important point when trying to optimize individual patient’s treatment regime. This interview took place during the ACTRIMS Forum 2021.
